ß1 integrins as therapeutic targets to disrupt hallmarks of cancer

Frontiers in Pharmacology

Volumn 6, Issue NOV, 2015, Pages

  Blandin, Anne Florence ^a   Renner, Guillaume ^a   Lehmann, Maxime ^a   Lelong Rebel, Isabelle ^a   Martin, Sophie ^a   Dontenwill, Monique ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Angiogenesis; Hallmarks of cancer; Integrins; Migrationinvasion; Proliferation; Resistance to cell death; Therapeutic target

Indexed keywords

BETA1 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; PROTEIN P53; TUMOR MARKER;

APOPTOSIS; CANCER GROWTH; CELL ADHESION; CELL SURVIVAL; DRUG RESISTANCE; ENERGY METABOLISM; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; METASTASIS; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RADIOSENSITIVITY; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR IMMUNITY; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84949769085     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00279     Document Type: Short Survey

References (144)

1. Ahmadizar, F., Onland-Moret, N. C., de Boer, A., Liu, G., and Maitland-van der Zee, A. H. (2015). Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 10:e0136324. doi: 10.1371/journal.pone.0136324
2. Ahmed, K. M., Zhang, H., and Park, C. C. (2013). NF-kappaB regulates radioresistance mediated by beta1-integrin in three-dimensional culture of breast cancer cells. Cancer Res. 73, 3737-3748. doi: 10.1158/0008-5472.CAN-12-3537
3. Alanko, J., Mai, A., Jacquemet, G., Schauer, K., Kaukonen, R., Saari, M., et al. (2015). Integrin endosomal signalling suppresses anoikis. Nat. Cell Biol. 17, 1412-1421. doi: 10.1038/ncb3250
4. Alexander, S., and Friedl, P. (2012). Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol. Med. 18, 13-26. doi: 10.1016/j.molmed.2011.11.003
5. Anikeeva, N., Steblyanko, M., Fayngerts, S., Kopylova, N., Marshall, D. J., Powers, G. D., et al. (2014). Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity. Eur. J. Immunol. 44, 2331-2339. doi: 10.1002/eji.201344179
6. Aoudjit, F., and Vuori, K. (2012). Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012:283181. doi: 10.1155/2012/283181
7. Aslan, B., Monroig, P., Hsu, M. C., Pena, G. A., Rodriguez-Aguayo, C., Gonzalez-Villasana, V., et al. (2015). The ZNF304-integrin axis protects against anoikis in cancer. Nat. Commun. 6, 7351. doi: 10.1038/ncomms8351
8. Atkinson, S. J., Ellison, T. S., Steri, V., Gould, E., and Robinson, S. D. (2014). Redefining the role(s) of endothelial alphavbeta3-integrin in angiogenesis. Biochem. Soc. Trans. 42, 1590-1595. doi: 10.1042/BST2010206
9. Avraamides, C. J., Garmy-Susini, B., and Varner, J. A. (2008). Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8, 604-617. doi: 10.1038/nrc2353
10. Barkan, D., and Chambers, A. F. (2011). beta1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin. Cancer Res. 17, 7219-7223. doi: 10.1158/1078-0432.CCR-11-0642
11. Bogorad, R. L., Yin, H., Zeigerer, A., Nonaka, H., Ruda, V. M., Zerial, M., et al. (2014). Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nat. Commun. 5, 3869. doi: 10.1038/ncomms4869
12. Borrirukwanit, K., Pavasant, P., Blick, T., Lafleur, M. A., and Thompson, E. W. (2014). High threshold of beta1 integrin inhibition required to block collagen I-induced membrane type-1 matrix metalloproteinase (MT1-MMP) activation of matrix metalloproteinase 2 (MMP-2). Cancer Cell Int. 14:99. doi: 10.1186/s12935-014-0099-3
13. Brennan, C. W., Verhaak, R. G., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., et al. (2013). The somatic genomic landscape of glioblastoma. Cell 155, 462-477. doi: 10.1016/j.cell.2013.09.034
14. Buchheit, C. L., Weigel, K. J., and Schafer, Z. T. (2014). Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat. Rev. Cancer 14, 632-641. doi: 10.1038/nrc3789
15. Cantor, J. M., Rose, D. M., Slepak, M., and Ginsberg, M. H. (2015). Fine-tuning tumor immunity with integrin trans-regulation. Cancer Immunol. Res. 3, 661-667. doi: 10.1158/2326-6066.CIR-13-0226
16. Carbonell, W. S., DeLay, M., Jahangiri, A., Park, C. C., and Aghi, M. K. (2013). beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 73, 3145-3154. doi: 10.1158/0008-5472.CAN-13-0011
17. Caswell, P. T., Chan, M., Lindsay, A. J., McCaffrey, M. W., Boettiger, D., and Norman, J. C. (2008). Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J. Cell Biol. 183, 143-155. doi: 10.1083/jcb.200804140
18. Chen, C. C., Kim, K. H., and Lau, L. F. (2015). The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene. doi: 10.1038/onc.2015.190. [Epub ahead of print].
19. Cheng, Y. J., Zhu, Z. X., Zhou, J. S., Hu, Z. Q., Zhang, J. P., Cai, Q. P., et al. (2015). Silencing profilin-1 inhibits gastric cancer progression via integrin beta1/focal adhesion kinase pathway modulation. World J. Gastroenterol. 21, 2323-2335. doi: 10.3748/wjg.v21.i8.2323
20. Ciriello, G., Miller, M. L., Aksoy, B. A., Senbabaoglu, Y., Schultz, N., and Sander, C. (2013). Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127-1133. doi: 10.1038/ng.2762
21. de Groot, J. F., Fuller, G., Kumar, A. J., Piao, Y., Eterovic, K., Ji, Y., et al. (2010). Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 12, 233-242. doi: 10.1093/neuonc/nop027
22. DeLay, M., Jahangiri, A., Carbonell, W. S., Hu, Y. L., Tsao, S., Tom, M. W., et al. (2012). Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin. Cancer Res. 18, 2930-2942. doi: 10.1158/1078-0432.CCR-11-2390
23. Desgrosellier, J. S., and Cheresh, D. A. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22. doi: 10.1038/nrc2748
24. Dickreuter, E., Eke, I., Krause, M., Borgmann, K., van Vugt, M. A., and Cordes, N. (2015). Targeting of beta1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Oncogene. doi: 10.1038/onc.2015.212. [Epub ahead of print].
25. Dong, X., Hudson, N. E., Lu, C., and Springer, T. A. (2014). Structural determinants of integrin beta-subunit specificity for latent TGF-beta. Nat. Struct. Mol. Biol. 21, 1091-1096. doi: 10.1038/nsmb.2905
26. Ducassou, A., Uro-Coste, E., Verrelle, P., Filleron, T., Benouaich-Amiel, A., Lubrano, V., et al. (2013). alphavbeta3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma. Eur. J. Cancer 49, 2161-2169. doi: 10.1016/j.ejca.2013.02.033
27. Eberwein, P., Laird, D., Schulz, S., Reinhard, T., Steinberg, T., and Tomakidi, P. (2015). Modulation of focal adhesion constituents and their down-stream events by EGF: on the cross-talk of integrins and growth factor receptors. Biochim. Biophys. Acta 1853, 2183-2198. doi: 10.1016/j.bbamcr.2015.06.004
28. Eke, I., and Cordes, N. (2015). Focal adhesion signaling and therapy resistance in cancer. Semin. Cancer Biol. 31, 65-75. doi: 10.1016/j.semcancer.2014.07.009
29. Eke, I., Deuse, Y., Hehlgans, S., Gurtner, K., Krause, M., Baumann, M., et al. (2012). beta(1)Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J. Clin. Invest. 122, 1529-1540. doi: 10.1172/JCI61350
30. Eke, I., Storch, K., Krause, M., and Cordes, N. (2013). Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis. Cancer Res. 73, 5869-5879. doi: 10.1158/0008-5472.CAN-13-0344
31. Eke, I., Zscheppang, K., Dickreuter, E., Hickmann, L., Mazzeo, E., Unger, K., et al. (2015). Simultaneous beta1 integrin-EGFR targeting and radiosensitization of human head and neck cancer. J. Natl. Cancer Inst. 107:dju419. doi: 10.1093/jnci/dju419
32. Esposito, M., and Kang, Y. (2014). Targeting tumor-stromal interactions in bone metastasis. Pharmacol. Ther. 141, 222-233. doi: 10.1016/j.pharmthera.2013.10.006
33. Fabricius, E. M., Wildner, G. P., Kruse-Boitschenko, U., Hoffmeister, B., Goodman, S. L., and Raguse, J. D. (2011). Immunohistochemical analysis of integrins alphavbeta3, alphavbeta5 and alpha5beta1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp. Ther. Med. 2, 9-19. doi: 10.3892/etm.2010.171
34. Fedorenko, I. V., Abel, E. V., Koomen, J. M., Fang, B., Wood, E. R., Chen, Y. A., et al. (2015). Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. doi: 10.1038/onc.2015.188. [Epub ahead of print].
35. Fennewald, S. M., Kantara, C., Sastry, S. K., and Resto, V. A. (2012). Laminin interactions with head and neck cancer cells under low fluid shear conditions lead to integrin activation and binding. J. Biol. Chem. 287, 21058-21066. doi: 10.1074/jbc. M112.360313
36. Gillory, L. A., Stewart, J. E., Megison, M. L., Waters, A. M., and Beierle, E. A. (2015). Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival. J. Surg. Res. 196, 339-349. doi: 10.1016/j.jss.2015.03.021
37. Golubovskaya, V. M. (2014). Targeting FAK in human cancer: from finding to first clinical trials. Front. Biosci. 19, 687-706. doi: 10.2741/4236
38. Golubovskaya, V. M., and Cance, W. G. (2011). FAK and p53 protein interactions. Anticancer. Agents Med. Chem. 11, 617-619. doi: 10.2174/187152011796817619
39. Golubovskaya, V. M., Finch, R., Kweh, F., Massoll, N. A., Campbell-Thompson, M., Wallace, M. R., et al. (2008). p53 regulates FAK expression in human tumor cells. Mol. Carcinog. 47, 373-382. doi: 10.1002/mc.20395
40. Griffiths, G. S., Grundl, M., Leychenko, A., Reiter, S., Young-Robbins, S. S., Sulzmaier, F. J., et al. (2011). Bit-1 mediates integrin-dependent cell survival through activation of the NFkappaB pathway. J. Biol. Chem. 286, 14713-14723. doi: 10.1074/jbc. M111.228387
41. Guo, G., Gong, K., Wohlfeld, B., Hatanpaa, K. J., Zhao, D., and Habib, A. A. (2015). Ligand-Independent EGFR Signaling. Cancer Res. 75, 3436-3441. doi: 10.1158/0008-5472.CAN-15-0989
42. Hakanpaa, L., Sipila, T., Leppanen, V. M., Gautam, P., Nurmi, H., Jacquemet, G., et al. (2015). Endothelial destabilization by angiopoietin-2 via integrin beta1 activation. Nat. Commun. 6, 5962. doi: 10.1038/ncomms6962
43. Han, S., Li, Z., Master, L. M., Master, Z. W., and Wu, A. (2014). Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway. Br. J. Cancer. 111, 1400-1409. doi: 10.1038/bjc.2014.435
44. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70. doi: 10.1016/S0092-8674(00)81683-9
45. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013
46. Hanein, D., and Horwitz, A. R. (2012). The structure of cell-matrix adhesions: the new frontier. Curr. Opin. Cell Biol. 24, 134-140. doi: 10.1016/j.ceb.2011.12.001
47. Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., et al. (2015). Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell. 27, 574-588. doi: 10.1016/j.ccell.2015.03.008
48. Hohenester, E. (2014). Signalling complexes at the cell-matrix interface. Curr. Opin. Struct. Biol. 29, 10-16. doi: 10.1016/j.sbi.2014.08.009
49. Holmes, K. M., Annala, M., Chua, C. Y., Dunlap, S. M., Liu, Y., Hugen, N., et al. (2012). Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kappaB network. Proc. Natl. Acad. Sci. U.S.A. 109, 3475-3480. doi: 10.1073/pnas.1120375109
50. Hongu, T., Funakoshi, Y., Fukuhara, S., Suzuki, T., Sakimoto, S., Takakura, N., et al. (2015). Arf6 regulates tumour angiogenesis and growth through HGF-induced endothelial beta1 integrin recycling. Nat. Commun. 6, 7925. doi: 10.1038/ncomms8925
51. Howe, G. A., and Addison, C. L. (2012). beta1 integrin: an emerging player in the modulation of tumorigenesis and response to therapy. Cell Adh. Migr. 6, 71-77. doi: 10.4161/cam.20077
52. Hu, C., Ni, Z., Li, B. S., Yong, X., Yang, X., Zhang, J. W., et al. (2015). hTERT promotes the invasion of gastric cancer cells by enhancing FOXO3a ubiquitination and subsequent ITGB1 upregulation. Gut. doi: 10.1136/gutjnl-2015-309322. [Epub ahead of print].
53. Huang, C., Park, C. C., Hilsenbeck, S. G., Ward, R., Rimawi, M. F., Wang, Y. C., et al. (2011). beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 13, R84. doi: 10.1186/bcr2936
54. Huang, C. R., Lee, C. T., Chang, K. Y., Chang, W. C., Liu, Y. W., Lee, J. C., et al. (2015). Down-regulation of ARNT promotes cancer metastasis by activating the fibronectin/integrin beta1/FAK axis. Oncotarget 6, 11530-11546. doi: 10.18632/oncotarget.3448
55. Ivanova, I. A., Vermeulen, J. F., Ercan, C., Houthuijzen, J. M., Saig, F. A., Vlug, E. J., et al. (2013). FER kinase promotes breast cancer metastasis by regulating alpha6-and beta1-integrin-dependent cell adhesion and anoikis resistance. Oncogene 32, 5582-5592. doi: 10.1038/onc.2013.277
56. Ivaska, J., and Heino, J. (2011). Cooperation between integrins and growth factor receptors in signaling and endocytosis. Annu. Rev. Cell Dev. Biol. 27, 291-320. doi: 10.1146/annurev-cellbio-092910-154017
57. Jachetti, E., Caputo, S., Mazzoleni, S., Brambillasca, C. S., Parigi, S. M., Grioni, M., et al. (2015). Tenascin-C protects cancer stem-like cells from immune surveillance by arresting T-cell activation. Cancer Res. 75, 2095-2108. doi: 10.1158/0008-5472.CAN-14-2346
58. Jahangiri, A., Aghi, M. K., and Carbonell, W. S. (2014). beta1 integrin: critical path to antiangiogenic therapy resistance and beyond. Cancer Res. 74, 3-7. doi: 10.1158/0008-5472.CAN-13-1742
59. Janes, S. M., and Watt, F. M. (2004). Switch from alphavbeta5 to alphavbeta6 integrin expression protects squamous cell carcinomas from anoikis. J. Cell Biol. 166, 419-431. doi: 10.1083/jcb.200312074
60. Janouskova, H., Maglott, A., Leger, D. Y., Bossert, C., Noulet, F., Guerin, E., et al. (2012). Integrin alpha5beta1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer Res. 72, 3463-3470. doi: 10.1158/0008-5472.CAN-11-4199
61. Janouskova, H., Ray, A. M., Noulet, F., Lelong-Rebel, I., Choulier, L., Schaffner, F., et al. (2013). Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target alpha5 integrin in colon cancer cells. Cancer Lett. 336, 307-318. doi: 10.1016/j.canlet.2013.03.018
62. Jinushi, M., Chiba, S., Baghdadi, M., Kinoshita, I., Dosaka-Akita, H., Ito, K., et al. (2012). ATM-mediated DNA damage signals mediate immune escape through integrin-alphavbeta3-dependent mechanisms. Cancer Res. 72, 56-65. doi: 10.1158/0008-5472.CAN-11-2028
63. Ju, L., and Zhou, C. (2013). Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell Int. 13:15. doi: 10.1186/1475-2867-13-15
64. Jung, A., Ray, A. M., Ramolu, L., Macabre, C., Simon, F., Noulet, F., et al. (2015). Caveolin-1-negative head and neck squamous cell carcinoma primary tumors display increased EMT and pro-metastatic properties. Oncotarget. doi: 10.18632/oncotarget.6099. [Epub ahead of print].
65. Kanda, R., Kawahara, A., Watari, K., Murakami, Y., Sonoda, K., Maeda, M., et al. (2013). Erlotinib resistance in lung cancer cells mediated by integrin beta1/Src/Akt-driven bypass signaling. Cancer Res. 73, 6243-6253. doi: 10.1158/0008-5472.CAN-12-4502
66. Lahlou, H., and Muller, W. J. (2011). beta1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Research 13, 229. doi: 10.1186/bcr2905
67. Lanvin, O., Monferran, S., Delmas, C., Couderc, B., Toulas, C., and Cohen-Jonathan-Moyal, E. (2013). Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells. Eur. J. Cancer. 49, 2884-2891. doi: 10.1016/j.ejca.2013.05.003
68. Lee, J. G., Ahn, J. H., Jin Kim, T., Ho Lee, J., and Choi, J. H. (2015). Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin beta4 and Akt signals. Sci. Rep. 5:12642. doi: 10.1038/srep12642
69. Leyme, A., Marivin, A., Perez-Gutierrez, L., Nguyen, L. T., and Garcia-Marcos, M. (2015). Integrins activate trimeric G proteins via the nonreceptor protein GIV/Girdin. J. Cell Biol. 210, 1165-1184. doi: 10.1083/jcb.201506041
70. Li, X., Ishihara, S., Yasuda, M., Nishioka, T., Mizutani, T., Ishikawa, M., et al. (2013). Lung cancer cells that survive ionizing radiation show increased integrin alpha2beta1-and EGFR-dependent invasiveness. PLoS ONE. 8:e70905. doi: 10.1371/journal.pone.0070905
71. Liu, C. C., Leclair, P., Yap, S. Q., and Lim, C. J. (2013). The membrane-proximal KXGFFKR motif of alpha-integrin mediates chemoresistance. Mol. Cell. Biol. 33, 4334-4345. doi: 10.1128/MCB.00580-13
72. Ma, J., Cai, W., Zhang, Y., Huang, C., Zhang, H., Liu, J., et al. (2013). Innate immune cell-derived microparticles facilitate hepatocarcinoma metastasis by transferring integrin alpha(M)beta(2) to tumor cells. J. Immunol. 191, 3453-3461. doi: 10.4049/jimmunol.1300171
73. Mai, A., Muharram, G., Barrow-McGee, R., Baghirov, H., Rantala, J., Kermorgant, S., et al. (2014). Distinct c-Met activation mechanisms induce cell rounding or invasion through pathways involving integrins, RhoA and HIP1. J. Cell Sci. 127, 1938-1952. doi: 10.1242/jcs.140657
74. Martin, S., Janouskova, H., and Dontenwill, M. (2012). Integrins and p53 pathways in glioblastoma resistance to temozolomide. Front. Oncol. 2:157. doi: 10.3389/fonc.2012.00157
75. Martinkova, E., Maglott, A., Leger, D. Y., Bonnet, D., Stiborova, M., Takeda, K., et al. (2010). alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int. J. Cancer J. Int. du Cancer 127, 1240-1248. doi: 10.1002/ijc.25187
76. McGrail, D. J., Khambhati, N. N., Qi, M. X., Patel, K. S., Ravikumar, N., Brandenburg, C. P., et al. (2015). Alterations in ovarian cancer cell adhesion drive taxol resistance by increasing microtubule dynamics in a FAK-dependent manner. Sci. Rep. 5:9529. doi: 10.1038/srep09529
77. Missan, D. S., Mitchell, K., Subbaram, S., and DiPersio, C. M. (2015). Integrin alpha3beta1 signaling through MEK/ERK determines alternative polyadenylation of the MMP-9 mRNA transcript in immortalized mouse keratinocytes. PLoS ONE 10:e0119539. doi: 10.1371/journal.pone.0119539
78. Monferran, S., Skuli, N., Delmas, C., Favre, G., Bonnet, J., Cohen-Jonathan-Moyal, E., et al. (2008). Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int. J. Cancer J. Int. du Cancer 123, 357-364. doi: 10.1002/ijc.23498
79. Morello, V., Cabodi, S., Sigismund, S., Camacho-Leal, M. P., Repetto, D., Volante, M., et al. (2011). beta1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 30, 4087-4096. doi: 10.1038/onc.2011.107
80. Moreno-Layseca, P., and Streuli, C. H. (2014). Signalling pathways linking integrins with cell cycle progression. Matrix Biol. 34, 144-153. doi: 10.1016/j.matbio.2013.10.011
81. Moro, L., Dolce, L., Cabodi, S., Bergatto, E., Boeri Erba, E., Smeriglio, M., et al. (2002). Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J. Biol. Chem. 277, 9405-9414. doi: 10.1074/jbc. M109101200
82. Morozevich, G. E., Kozlova, N. I., Susova, O. Y., Karalkin, P. A., and Berman, A. E. (2015). Implication of alpha2beta1 integrin in anoikis of MCF-7 human breast carcinoma cells. Biochem. Biokhimiia. 80, 97-103. doi: 10.1134/S0006297915010113
83. Morozevich, G. E., Kozlova, N. I., Ushakova, N. A., Preobrazhenskaya, M. E., and Berman, A. E. (2012). Integrin alpha5beta1 simultaneously controls EGFR-dependent proliferation and Akt-dependent pro-survival signaling in epidermoid carcinoma cells. Aging. 4, 368-374.
84. Muharram, G., Sahgal, P., Korpela, T., De Franceschi, N., Kaukonen, R., Clark, K., et al. (2014). Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells. Dev. Cell 29, 421-436. doi: 10.1016/j.devcel.2014.03.024
85. Murphy, P. A., Begum, S., and Hynes, R. O. (2015). Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors. PLoS ONE 10:e0120872. doi: 10.1371/journal.pone.0120872
86. Naci, D., El Azreq, M. A., Chetoui, N., Lauden, L., Sigaux, F., Charron, D., et al. (2012). alpha2beta1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J. Biol. Chem. 287, 17065-17076. doi: 10.1074/jbc. M112.349365
87. Naci, D., Vuori, K., and Aoudjit, F. (2015). Alpha2beta1 integrin in cancer development and chemoresistance. Semin. Cancer Biol. 35, 145-153. doi: 10.1016/j.semcancer.2015.08.004
88. Nam, J. M., Ahmed, K. M., Costes, S., Zhang, H., Onodera, Y., Olshen, A. B., et al. (2013). beta1-Integrin via NF-kappaB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer. Breast Cancer Res. 15, R60. doi: 10.1186/bcr3454
89. Nam, J. M., Chung, Y., Hsu, H. C., and Park, C. C. (2009). beta1 integrin targeting to enhance radiation therapy. Int. J. Radiat. Biol. 85, 923-928. doi: 10.3109/09553000903232876
90. Navab, R., Strumpf, D., To, C., Pasko, E., Kim, K. S., Park, C. J., et al. (2015). Integrin alpha11beta1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer. Oncogene. doi: 10.1038/onc.2015.254. [Epub ahead of print].
91. Ning, S., Tian, J., Marshall, D. J., and Knox, S. J. (2010). Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 70, 7591-7599. doi: 10.1158/0008-5472.CAN-10-1639
92. Nistico, P., Di Modugno, F., Spada, S., and Bissell, M. J. (2014). beta1 and beta4 integrins: from breast development to clinical practice. Breast Cancer Res. 16:459. doi: 10.1186/s13058-014-0459-x
93. Nunes, J. B., Peixoto, J., Soares, P., Maximo, V., Carvalho, S., Pinho, S. S., et al. (2015). OXPHOS dysfunction regulates integrin-beta1 modifications and enhances cell motility and migration. Hum. Mol. Genet. 24, 1977-1990. doi: 10.1093/hmg/ddu612
94. Oommen, S., Gupta, S. K., and Vlahakis, N. E. (2011). Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin α9β1: identification of a specific α9β1 binding site. J. Biol. Chem. 286, 1083-1092. doi: 10.1074/jbc. M110.175158
95. Paoli, P., Giannoni, E., and Chiarugi, P. (2013). Anoikis molecular pathways and its role in cancer progression. Biochim. Biophys. Acta. 1833, 3481-3498. doi: 10.1016/j.bbamcr.2013.06.026
96. Paul, N. R., Allen, J. L., Chapman, A., Morlan-Mairal, M., Zindy, E., Jacquemet, G., et al. (2015). alpha5beta1 integrin recycling promotes Arp2/3-independent cancer cell invasion via the formin FHOD3. J. Cell Biol. 210, 1013-1031. doi: 10.1083/jcb.201502040
97. Paulus, W., Baur, I., Schuppan, D., and Roggendorf, W. (1993). Characterization of integrin receptors in normal and neoplastic human brain. Am. J. Pathol. 143, 154-163.
98. Pelillo, C., Bergamo, A., Mollica, H., Bestagno, M., and Sava, G. (2015). Colorectal cancer metastases settle in the hepatic microenvironment through alpha5beta1 integrin. J. Cell. Biochem. 116, 2385-2396. doi: 10.1002/jcb.25189
99. Petrás, M., Lajtos, T., Friedländer, E., Klekner, A., Pintye, E., Feuerstein, B. G., et al. (2013). Molecular interactions of ErbB1 (EGFR) and integrin-beta1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance. Neuro Oncol. 15, 1027-1040. doi: 10.1093/neuonc/not046
100. Pickup, M. W., Mouw, J. K., and Weaver, V. M. (2014). The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15, 1243-1253. doi: 10.15252/embr.201439246
101. Poschau, M., Dickreuter, E., Singh-Mäller, J., Zscheppang, K., Eke, I., Liersch, T., et al. (2015). EGFR and beta1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion. Radiother. Oncol. 116, 510-516. doi: 10.1016/j.radonc.2015.06.005
102. Renner, G., Janouskova, H., Noulet, F., Koenig, V., Guerin, E., Bär, S., et al. (2015). Integrin alpha5beta1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma. Cell Death Different. doi: 10.1038/cdd.2015.131. [Epub ahead of print].
103. Robertson, J., Jacquemet, G., Byron, A., Jones, M. C., Warwood, S., Selley, J. N., et al. (2015). Defining the phospho-adhesome through the phosphoproteomic analysis of integrin signalling. Nat. Commun. 6, 6265. doi: 10.1038/ncomms7265
104. Robinson, S. D., Reynolds, L. E., Kostourou, V., Reynolds, A. R., da Silva, R. G., Tavora, B., et al. (2009). Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J. Biol. Chem. 284, 33966-33981. doi: 10.1074/jbc. M109.030700
105. Rossier, O., Octeau, V., Sibarita, J. B., Leduc, C., Tessier, B., Nair, D., et al. (2012). Integrins beta1 and beta3 exhibit distinct dynamic nanoscale organizations inside focal adhesions. Nat. Cell Biol. 14, 1057-1067. doi: 10.1038/ncb2588
106. Savar, A., Acin, S., Gonzalez, C. L., El-Sawy, T., Mejia, O., Li, Z., et al. (2015). Loss of epithelial p53 and alphav integrin cooperate through Akt to induce squamous cell carcinoma yet prevent remodeling of the tumor microenvironment. Oncogene 34, 516-524. doi: 10.1038/onc.2013.585
107. Scales, T. M., and Parsons, M. (2011). Spatial and temporal regulation of integrin signalling during cell migration. Curr. Opin. Cell Biol. 23, 562-568. doi: 10.1016/j.ceb.2011.05.008
108. Schaffner, F., Ray, A. M., and Dontenwill, M. (2013). Integrin alpha5beta1, the fibronectin receptor, as a pertinent therapeutic target in solid tumors. Cancers 5, 27-47. doi: 10.3390/cancers5010027
109. Schempp, C. M., von Schwarzenberg, K., Schreiner, L., Kubisch, R., Muller, R., Wagner, E., et al. (2014). V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Mol. Cancer Ther. 13, 926-937. doi: 10.1158/1535-7163.MCT-13-0484
110. Schlomann, U., Koller, G., Conrad, C., Ferdous, T., Golfi, P., Garcia, A. M., et al. (2015). ADAM8 as a drug target in pancreatic cancer. Nat. Commun. 6, 6175. doi: 10.1038/ncomms7175
111. Seguin, L., Desgrosellier, J. S., Weis, S. M., and Cheresh, D. A. (2015). Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 25, 234-240. doi: 10.1016/j.tcb.2014.12.006
112. Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., et al. (2014). An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 16, 457-468. doi: 10.1038/ncb2953
113. Selivanova, G. (2014). Wild type p53 reactivation: from lab bench to clinic. FEBS Lett. 588, 2628-2638. doi: 10.1016/j.febslet.2014.03.049
114. Shishido, S., Bönig, H., and Kim, Y. M. (2014). Role of integrin alpha4 in drug resistance of leukemia. Front. Oncol. 4:99. doi: 10.3389/fonc.2014.00099
115. Silginer, M., Weller, M., Ziegler, U., and Roth, P. (2014). Integrin inhibition promotes atypical anoikis in glioma cells. Cell Death Dis. 5, e1012. doi: 10.1038/cddis.2013.543
116. Skuli, N., Monferran, S., Delmas, C., Favre, G., Bonnet, J., Toulas, C., et al. (2009). Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res. 69, 3308-3316. doi: 10.1158/0008-5472.CAN-08-2158
117. Soares, M. Q., Mendonca, J. A., Morais, M. O., Leles, C. R., Batista, A. C., and Mendonca, E. F. (2015). E-cadherin, β-catenin, and a2β1 and a3β1 integrin expression in primary oral squamous cell carcinoma and its regional metastasis. Histol. Histopathol. 30, 1213-1222. doi: 10.14670/HH-11-616
118. Sørensen, B. H., Rasmussen, L. J., Broberg, B. S., Klausen, T. K., Sauter, D. P., Lambert, I. H., et al. (2015). Integrin beta1, osmosensing, and chemoresistance in mouse ehrlich carcinoma cells. Cell. Physiol. Biochem. 36, 111-132. doi: 10.1159/000374057
119. Speicher, T., Siegenthaler, B., Bogorad, R. L., Ruppert, R., Petzold, T., Padrissa-Altes, S., et al. (2014). Knockdown and knockout of beta1-integrin in hepatocytes impairs liver regeneration through inhibition of growth factor signalling. Nat. Commun. 5, 3862. doi: 10.1038/ncomms4862
120. Steglich, A., Vehlow, A., Eke, I., and Cordes, N. (2015). alpha integrin targeting for radiosensitization of three-dimensionally grown human head and neck squamous cell carcinoma cells. Cancer Lett. 357, 542-548. doi: 10.1016/j.canlet.2014.12.009
121. Steri, V., Ellison, T. S., Gontarczyk, A. M., Weilbaecher, K., Schneider, J. G., Edwards, D., et al. (2014). Acute depletion of endothelial beta3-integrin transiently inhibits tumor growth and angiogenesis in mice. Circ. Res. 114, 79-91. doi: 10.1161/CIRCRESAHA.114.301591
122. Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y. K., et al. (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol.15, 1100-1108. doi: 10.1016/S1470-2045(14)70379-1
123. Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M., et al. (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712-2718. doi: 10.1200/JCO.2009.26.6650
124. Tanaka, R., Seki, Y., Saito, Y., Kamiya, S., Fujita, M., Okutsu, H., et al. (2014). Tenascin-C-derived peptide TNIIIA2 highly enhances cell survival and platelet-derived growth factor (PDGF)-dependent cell proliferation through potentiated and sustained activation of integrin alpha5beta1. J. Biol. Chem. 289, 17699-17708. doi: 10.1074/jbc. M113.546622
125. Toricelli, M., Melo, F. H., Peres, G. B., Silva, D. C., and Jasiulionis, M. G. (2013). Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol. Cancer 12:22. doi: 10.1186/1476-4598-12-22
126. Tseng, P. C., Chen, C. L., Shan, Y. S., Chang, W. T., Liu, H. S., Hong, T. M., et al. (2014). An increase in integrin-linked kinase non-canonically confers NF-kappaB-mediated growth advantages to gastric cancer cells by activating ERK1/2. Cell Commun. Signal. 12:69. doi: 10.1186/s12964-014-0069-3
127. Vachon, P. H. (2011). Integrin signaling, cell survival, and anoikis: distinctions, differences, and differentiation. J. Signal Transduct. 2011:738137. doi: 10.1155/2011/738137
128. Veevers-Lowe, J., Ball, S. G., Shuttleworth, A., and Kielty, C. M. (2011). Mesenchymal stem cell migration is regulated by fibronectin through alpha5beta1-integrin-mediated activation of PDGFR-beta and potentiation of growth factor signals. J. Cell Sci. 124, 1288-1300. doi: 10.1242/jcs.076935
129. Vial, D., and McKeown-Longo, P. J. (2012). Epidermal growth factor (EGF) regulates alpha5beta1 integrin activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin A. J. Biol. Chem. 287, 40371-40380. doi: 10.1074/jbc. M112.389577
130. Vitorino, P., Yeung, S., Crow, A., Bakke, J., Smyczek, T., West, K., et al. (2015). MAP4K4 regulates integrin-FERM binding to control endothelial cell motility. Nature 519, 425-430. doi: 10.1038/nature14323
131. Vlahakis, N. E., Young, B. A., Atakilit, A., and Sheppard, D. (2005). The lymphangiogenic vascular endothelial growth factors VEGF-C and-D are ligands for the integrin alpha9beta1. J. Biol. Chem. 280, 4544-4552. doi: 10.1074/jbc. M412816200
132. Wang, Y., Arjonen, A., Pouwels, J., Ta, H., Pausch, P., Bange, G., et al. (2015). Formin-like 2 Promotes beta1-Integrin trafficking and invasive motility downstream of PKCalpha. Dev. Cell 34, 475-483. doi: 10.1016/j.devcel.2015.06.015
133. Williams, K. C., and Coppolino, M. G. (2014). SNARE-dependent interaction of Src, EGFR and beta1 integrin regulates invadopodia formation and tumor cell invasion. J. Cell Sci. 127, 1712-1725. doi: 10.1242/jcs.134734
134. Winograd-Katz, S. E., Fässler, R., Geiger, B., and Legate, K. R. (2014). The integrin adhesome: from genes and proteins to human disease. Nat. Rev. Mol. Cell Biol. 15, 273-288. doi: 10.1038/nrm3769
135. Wong, P. P., Demircioglu, F., Ghazaly, E., Alrawashdeh, W., Stratford, M. R., Scudamore, C. L., et al. (2015). Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 27, 123-137. doi: 10.1016/j.ccell.2014.10.015
136. Yamamoto, H., Ehling, M., Kato, K., Kanai, K., van Lessen, M., Frye, M., et al. (2015). Integrin beta1 controls VE-cadherin localization and blood vessel stability. Nat. Commun. 6, 6429. doi: 10.1038/ncomms7429
137. Yang, L., Hou, Y., Yuan, J., Tang, S., Zhang, H., Zhu, Q., et al. (2015). Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways. Oncotarget 6, 25755-25769. doi: 10.18632/oncotarget.4697
138. Yang, P., Li, Z., Fu, R., Wu, H., and Li, Z. (2014). Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. Cell. Signal. 26, 1853-1862. doi: 10.1016/j.cellsig.2014.03.020
139. Yuan, J., Liu, M., Yang, L., Tu, G., Zhu, Q., Chen, M., et al. (2015). Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and beta1-integrin signaling pathway in tumor cells. Breast Cancer Res. 17, 69. doi: 10.1186/s13058-015-0579-y
140. Zhang, H. F., Alshareef, A., Wu, C., Li, S., Jiao, J. W., Cao, H. H., et al. (2015a). Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin beta1/AKT pathway in esophageal squamous cell carcinoma: an E-cadherin-independent mechanism. Oncotarget 6, 28949-28960. doi: 10.18632/oncotarget.5027
141. Zhang, X., Cheng, S. L., Bian, K., Wang, L., Zhang, X., Yan, B., et al. (2015b). MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin. Oncotarget. 6, 2277-2289. doi: 10.18632/oncotarget.2956
142. Zhou, P., Erfani, S., Liu, Z., Jia, C., Chen, Y., Xu, B., et al. (2015). CD151-alpha3beta1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion. Oncotarget 6, 29675-29693. doi: 10.18632/oncotarget.4896
143. Zhu, J., and Clark, R. A. (2014). Fibronectin at select sites binds multiple growth factors and enhances their activity: expansion of the collaborative ECM-GF paradigm. J. Invest. Dermatol. 134, 895-901. doi: 10.1038/jid.2013.484
144. Zoni, E., van der Horst, G., van de Merbel, A. F., Chen, L., Rane, J. K., Pelger, R. C., et al. (2015). miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of alphav-and alpha6-Integrin expression. Cancer Res. 75, 2326-2336. doi: 10.1158/0008-5472.CAN-14-2155